Want to see IN:TARSONS full AI Analyst Report?
Top Page
Tarsons Products Limited
(TARSONS)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹350.00
▲(11.98% Upside)
Action:Reiterated
Date:07/22/26
The score is held back primarily by weakening financial performance (lower profitability, rising debt, and persistent negative free cash flow) and a very expensive valuation (high P/E). These risks are partly offset by strong technical momentum, with the stock trading above key moving averages and a positive MACD.
Positive Factors
Recurring consumables demand
Tarsons serves recurring laboratory workflows where consumables must be replenished regularly. This repeat-purchase model can support durable demand, improve customer retention, and provide a foundation for cross-selling its wider labware portfolio.
Negative Factors
Weakening profitability
The sharp decline in earnings and lower operating profit indicate that revenue growth is not translating into sustainable profitability. Persistent margin pressure could limit reinvestment capacity and reduce the benefits of scale across the product portfolio.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables demand
Tarsons serves recurring laboratory workflows where consumables must be replenished regularly. This repeat-purchase model can support durable demand, improve customer retention, and provide a foundation for cross-selling its wider labware portfolio.
Read all positive factors
Tarsons Products Limited (TARSONS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.82B
Dividend Yield0.42%
Average Volume (3M)27.83K
Price to Earnings (P/E)159.6
Beta (1Y)0.90
Revenue Growth10.63%
EPS Growth-59.63%
CountryIN
Employees823
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.70
Shares Outstanding53,206,280
10 Day Avg. Volume9,035
30 Day Avg. Volume27,828
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Tarsons Products Limited Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features ...
How the Company Makes Money
Tarsons makes money primarily by manufacturing and selling laboratory consumables (largely plastic, single-use and repeat-purchase items) to customers such as research labs, diagnostic labs, hospitals, academic institutions, and life-science/bioph...
Tarsons Products Limited Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
55
Neutral
Cash Flow
42
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.23B | 3.92B | 2.96B | 2.83B | 3.01B |
| Gross Profit | 1.12B | 1.35B | 985.42M | 2.18B | 1.49B |
| EBITDA | 1.18B | 1.27B | 1.11B | 1.42B | 1.61B |
| Net Income | 143.22M | 297.70M | 426.40M | 807.14M | 1.01B |
Balance Sheet | |||||
| Total Assets | 11.86B | 10.80B | 9.72B | 7.26B | 5.44B |
| Cash, Cash Equivalents and Short-Term Investments | 252.56M | 256.52M | 226.11M | 590.58M | 774.42M |
| Total Debt | 3.93B | 3.39B | 2.69B | 1.11B | 216.65M |
| Total Liabilities | 5.51B | 4.50B | 3.59B | 1.56B | 543.96M |
| Stockholders Equity | 6.35B | 6.30B | 6.13B | 5.69B | 4.90B |
Cash Flow | |||||
| Free Cash Flow | -71.03M | -550.87M | -816.28M | -1.14B | -485.02M |
| Operating Cash Flow | 1.18B | 966.20M | 1.03B | 755.99M | 834.67M |
| Investing Cash Flow | -1.30B | -1.47B | -2.85B | -1.79B | -1.38B |
| Financing Cash Flow | 89.33M | 578.12M | 1.36B | 845.61M | 1.30B |
Tarsons Products Limited Technical Analysis
Neutral
312.55
Price Trends
316.05
Positive
269.08
Positive
238.80
Positive
Market Momentum
6.14
Positive
49.67
Neutral
32.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Neutral. The current price of 312.55 is below the 20-day moving average (MA) of 336.52, below the 50-day MA of 316.05, and above the 200-day MA of 238.80, indicating a neutral trend. The MACD of 6.14 indicates Positive momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 32.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TARSONS.
Tarsons Products Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | ₹28.40B | 35.81 | ― | 0.31% | 14.22% | 7.17% | |
78 Outperform | ₹172.51B | 54.68 | ― | 0.21% | 18.31% | -12.86% | |
56 Neutral | ₹23.58B | 78.97 | ― | 0.01% | 195.95% | 1521.20% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₹17.82B | 159.62 | ― | 0.42% | 10.63% | -59.63% | |
50 Neutral | ₹6.74B | 152.74 | ― | 0.15% | 7.55% | -57.19% | |
39 Underperform | ₹1.21B | -8.43 | ― | ― | -29.72% | 47.94% |
* General Sector Average
IN:TARSONS
Tarsons Products Limited
326.00
9.50
3.00%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
55.69
-17.06
-23.45%
IN:POLYMED
Poly Medicure Limited
1,730.20
-266.94
-13.37%
IN:VIMTALABS
Vimta Labs Limited
626.30
-194.27
-23.68%
IN:ZIMLAB
Zim Laboratories Ltd.
129.15
54.28
72.50%
IN:FISCHER
Fischer Medical Ventures Ltd
35.52
-77.99
-68.71%
Tarsons Products Limited Corporate Events
Tarsons Products Publishes Q1 FY27 Investor Presentation for Market Disclosure
Aug 10, 2026
Tarsons Products Limited has released an investor presentation detailing its financial results for the quarter ended June 30, 2026, and submitted the same to both the BSE and NSE in line with SEBI disclosure regulations. The document, prepared und...
Tarsons Posts Q1 FY27 Results and Sets Date for 43rd AGM
Aug 10, 2026
Tarsons Products Limited reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as approved by its board of directors in a meeting held on August 10, 2026. The results, accompanied by a limited re...
Tarsons Says Share Price Surge Is Market-Driven, Affirms Full Regulatory Compliance
Jun 18, 2026
Tarsons Products Limited has responded to a query from the National Stock Exchange regarding significant price movement in its shares, asserting that it consistently complies with disclosure requirements under Regulation 30 of the SEBI Listing Reg...
Tarsons attributes share volume surge to market forces, affirms full regulatory compliance
Jun 18, 2026
Tarsons Products Limited has responded to a query from the National Stock Exchange of India after a significant increase in trading volume of its shares. The company stated that it has fully complied with disclosure requirements under SEBI’s...
Tarsons Schedules Virtual Investor Conference with Choice Broking
Jun 6, 2026
Tarsons Products Limited has informed stock exchanges that its officials will participate in an investor conference hosted by Choice Broking on June 11, 2026, via a virtual group meeting. The company stated that discussions with analysts and insti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.